Epzicom (Abacavir/3TC, Kivexa)

An Overview of Epzicom (Abacavir/3TC, Kivexa) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
FAQs About Epzicom (Abacavir/3TC, Kivexa) From The Body's "Ask the Experts" Forums (Regularly Updated)
From The Body's "Ask the Experts" Forums
Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
Epzicom/Kivexa (Abacavir + Lamivudine) (August 22, 2009)
To read PDF, click here
From AIDS InfoNet
Epzicom (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Epzicom (Abacavir/3TC, Kivexa) (PDF) (March 2009)
From GlaxoSmithKline
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
What's New in the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (November 3, 2008)
From AIDSinfo
Epzicom (Epivir + Ziagen) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
[Archived Article]
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
[Archived Article]
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
[Archived Article]
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group
FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
[Archived Article]
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News
FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
[Archived Article]
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO